Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1

Pediatric Infectious Disease Journal

Volumn 18, Issue 8, 1999, Pages 682-689

  Watson, Douglas C ^a   Farley, John J ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Adherence to therapy; Antiretrovirals; Human immunodeficiency virus infections; Protease inhibitors

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PROTEINASE INHIBITOR;

ARTICLE; CHILD; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; VIRUS LOAD;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INFANT; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0032775622     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199908000-00006     Document Type: Article

References (39)

1. Centers for Disease Control and Prevention. Report of the NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR 1998;47(RR-5):1-82.
2. Melvin AJ, Mohan KM, Arcuino LA, Edelstein RE, Frenkel LM. Clinical, virologic and immunologic responses of children with advanced human immunodeficiency virus type 1 disease treated with protease inhibitors. Pediatr Infect Dis J 1997; 16:968-74.
3. Luzuriaga K, Bryson Y, Krogstad P, et al. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. N Engl J Med 1997;336:1343-9.
4. Rutstein RM, Feingold A, Meislich D, Word B, Rudy B. Protease inhibitor therapy in children with perinatally acquired HIV infection. AIDS 1997;11:F107-11.
5. Mostashari F, Riley E, Selwyn PA, Altice FL. Acceptance and adherence with antiretroviral therapy among HIV-infected women in a correctional facility. J Acquir Immune Defic Syndr 1998;18:341-8.
6. Kline MW, Fletcher CV, Harris AT, et al. A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus. J Pediatr 1998;132:543-6.
7. Krogstad P, Wiznia AA, Luzuriaga K, et al. Evidence of potent antiviral activity in a phase I/II study of nelfinavir mesylate (Viracept) in HIV infected children [Abstract]. Presented at the Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1 to 5, 1998. Alexandria, VA: Foundation for Retrovirology and Human Health, 1998.
8. Pelton SI, Yogev R, Johnson D. Changes in Viral load and immunologic markers in children treated with triple therapy including ritonavir [Abstract]. Presented at the Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1 to 5, 1998. Alexandria, VA: Foundation for Retrovirology and Human Health, 1998.
9. Jankelevich S, Mueller B, Smith S, et al. Long-term activity of indinavir/ZDV/3TC in HIV-1 infected children: results of a Phase I/II study [Abstract]. Presented at the Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1 to 5, 1998. Alexandria, VA: Foundation for Retrovirology and Human Health, 1998.
10. Kline MW, Fletcher CV, Brundage RC, et al. Combination therapy including saquinavir soft gelatin capsules (SQV-SGC) in HIV infected children [Abstract]. Presented at the Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1 to 5, 1998. Alexandria, VA: Foundation for Retrovirology and Human Health, 1998.
11. + T cells following ritonavir therapy in HIV-infected children with advanced disease [Abstract]. Presented at the Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1 to 5, 1998. Alexandria, VA: Foundation for Retrovirology and Human Health, 1998.
12. Havens PL, Cuene BE. Efficacy of protease inhibitor therapy in children and adolescents with HIV infection [Abstract]. Proceedings of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 24 to 27, 1998. Washington, DC: American Society for Microbiology, 1998.
13. Centers for Disease Control and Prevention. Guidelines for the use of antiretroviral agents in pediatric HIV infection. MMWR 1998;47(RR-4):1-43.
14. Rowland-Jones S, Tan R, McMichael A. Role of cellular immunity in protection against HIV infection. Adv Immunol 1997;65:277-346.
15. Moore RD, Keruly JC, Gallant J, et al. Response to therapy with protease inhibitors in clinical practice [Abstract]. Presented at the Twelfth World AIDS Conference, Geneva, Switzerland, June 28 to July 3, 1998. Geneva: Twelfth International Conference on AIDS Society, 1998.
16. Sackett DL, Haynes RB. Compliance with therapeutic regimens. Baltimore: Johns Hopkins University Press, 1976.
17. Parrish JM. Parent compliance with medical and behavioral recommendations. In: Parrish J, Krasnegor N, Arasteh J, Cataldo M, eds. Child health behavior: a behavioral pediatrics. New York: Wiley, 1986:453-501.
18. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
19. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997;337:725-33.
20. Singh N, Squier C, Sivek C, Wagener M, Nguyen MH, Yu VL. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care 1996;8:261-9.
21. Eldred LJ, Wu AW, Chaisson RE, Moore RD. Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. J Acquir Immune Defic Syndr 1998;18:117-25.
22. Tebas P, Royal M, Fichtenbaum J, et al. The value of early parameters of adherence in predicting successful response to highly active antiretroviral therapy (HAART) [Abstract]. Presented at the Twelfth World AIDS Conference, Geneva, Switzerland, June 28 to July 3, 1998. Geneva: Twelfth International Conference on AIDS Society, 1998.
23. Hecht FM, Colfax G, Swanson M, et al. Adherence and Effectiveness of protease inhibitors in clinical practice. [Abstract]. Presented at the Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1 to 5, 1998. Alexandria, VA: Foundation for Retrovirology and Human Health, 1998.
24. Fessel WJ, Hurley LB. Outcomes of Triple Therapy that included a protease inhibitor (PI) among 2139 patients. [Abstract]. Presented at the Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1 to 5, 1998. Alexandria, VA: Foundation for Retrovirology and Human Health, 1998.
25. Yogev R, Stanley SA, Nachman S, et al. Virologic efficacy of ZDV + 3TC vs. d4T + ritonavir (RTV) vs. ZDV + 3TC + RTV in stable antiretroviral experienced HIV-infected children (Pediatric ACTG Trial 338) [Abstract]. Presented at the Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1 to 5, 1998. Alexandria, VA: Foundation for Retrovirology and Human Health, 1998.
26. Mofenson LM, Korelitz J, Meyer WA, et al. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. J Infect Dis 1997;175:1029-38.
27. + lymphocyte count in HIV-infected infants and children. JAMA 1998;279:756-61.
28. Palumbo PE, Kwok S, Waters S, et al. Viral measurement by polymerase chain reaction-based assays in human immunodeficiency virus-infected infants. J Pediatr 1995;126:592-5.
29. Tetali S, Bakshi S, Than S, et al. Plasma virus load evaluation in relation to disease progression in HIV-infected children. AIDS Res Hum Retroviruses 1998;14:571-7.
30. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997;278:1291-5.
31. Shearer WT, Quinn TC, LaRussa P, et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1: Women and Infants Transmission Study Group. N Engl J Med 1997;336:1337-42.
32. Maeland A, Holberg M, Bruuni JN, et al. Subtle differences in low-level HIV viral load on treatment is important for outcome [Abstract]. Presented at the Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1 to 5, 1998. Alexandria, VA: Foundation for Retrovirology and Human Health, 1998.
33. Izopet J, Salama G, Pasquier C, et al. Ultra sensitive detection of plasma HIV-1 RNA for predicting the durability of 3-drug antiretroviral therapy [Abstract]. Presented at the Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1 to 5, 1998. Alexandria, VA: Foundation for Retrovirology and Human Health, 1998.
34. Kempf DJ, Rode RA, Xu Y, et al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 1998;12:F9-14.
35. Paterson DL, Swindles S, Mohr JA, et al. Adherence with protease inhibitor therapy for human immunodeficiency virus infection [Abstract]. In: 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 24 to 27, 1998. Washington, DC: American Society for Microbiology, 1998.
36. Charney E, Bynum R, Eldredge D, et al. How well do patients take oral penicillin? A collaborative study in private practice. Pediatrics 1967;40:188-95.
37. Essajee S, Kaul A, Rigaud M, et al. CD4 and viral phenotypic responses of HIV-1 infected children to antiretroviral therapy with and without protease inhibitors [Abstract]. In: 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 28 to October 1, 1997, Washington, DC: American Society for Microbiology, 1997.
38. Maggiolo F, Bottura P, Caprioli S, et al. HIV-RNA Serum levels correlate with CD4 T-cell counts [Abstract]. In: 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 24 to 27, 1998. Washington, DC: American Society for Microbiology, 1998.
39. Watson DW, Collins-Jones TL, Lovelace S. Antiretroviral therapy of pediatric HIV infection: making hope a reality. AIDS Care and STDs (In press).